复发/转移头颈部鳞癌治疗新希望

作者： 桂琳 来源：2024人民好医生肿瘤防治科普行动

责任编辑：桂琳

参考资料：1. 中国临床肿瘤学会(CSCO)头颈部肿瘤诊疗指南（2024年版） 2. 中国癌症基金会 中华护理学会肿瘤护理专委会 《肿瘤免疫治疗患者教育手册》 （2019年版） 3. 抗EGFR单抗治疗复发/转移性头颈部鳞状细胞癌临床共识(2021年版) 4. Tahara, M., et al. "659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048." Annals of Oncology 33 (2022): S844. 5. NCCN Guidelines Version2.2024 Head and Neck Cancers（美国国家综合癌症网络头颈部肿瘤临床实践指南2024年第2版） 6.Keam, B., et al. "Pan-Asian adaptation of the EHNS–ESMO–ESTRO （欧洲头颈学会-欧洲肿瘤内科学会-欧洲放疗肿瘤学学会 ）Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck." ESMO open 6.6 (2021): 100309. 7.Cohen, Ezra EW, et al. "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)." Journal for immunotherapy of cancer 7 (2019): 1-31. 8. Rivera, Fernando, et al. "Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial." Expert review of anticancer therapy 9.10 (2009): 1421-1428. 9. Guo, Ye, et al. "First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial." European Journal of Cancer 156 (2021): 35-45. 10. Lu, Haizhen, et al. "PD-L1 expression in recurrent or metastatic head and neck squamous cell carcinoma in China (EXCEED study): a multicentre retrospective study." Journal of Clinical Pathology (2023).